Antidyskinetic properties of topiramate: a double-blind, placebo-controlled trial in patients with Parkinson's disease and levodopa-induced dyskinesias

ISRCTN ISRCTN95151471
DOI https://doi.org/10.1186/ISRCTN95151471
Secondary identifying numbers 2007 Neuro 12
Submission date
20/05/2008
Registration date
02/07/2008
Last edited
09/05/2016
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Nervous System Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Montague Silverdale
Scientific

Salford Royal NHS Foundation Trust
Stott Lane
Salford
M6 8HD
United Kingdom

Phone +44 1625 661782
Email monty.silverdale@srft.nhs.uk

Study information

Study designMulticentre, randomised, double-blind, placebo-controlled, crossover study
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Not specified
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet.
Scientific titleAntidyskinetic properties of topiramate: a double-blind, placebo-controlled trial in patients with Parkinson's disease and levodopa-induced dyskinesias
Study objectivesLevodopa therapy is effective for the motor symptoms of Parkinson's disease. However, around half of patients develop abnormal involuntary movements, or dyskinesia, after 4 - 6 years of treatment. Current treatment interventions for this are not satisfactory in all cases.

Hypothesis:
Topiramate administration will attenuate levodopa-induced dyskinesia in patients with Parkinson's disease (PD) without worsening parkinsonism.
Ethics approval(s)Leeds (West) Research Ethics Committee, 24/01/2008, ref: 07/H1307/205
Health condition(s) or problem(s) studiedParkinson's disease and levodopa-induced dyskinesia
InterventionThis is a randomised, crossover study.

Topiramate group: start dose 25 mg/day orally (p.o.), to be up-titrated by 25 mg/day weekly to target dose of 100 mg/day in two divided doses. Participants to stay on maintenance dose for two weeks prior to assessment. Participants will attend having not taken usual morning medications, and response to these medications will then be assessed.

Control: placebo capsules, identical in appearance. To be titrated on same schedule as topiramate.

Following a two-week down-titration period, there will be a further two-week washout period before crossover.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Specified
Drug / device / biological / vaccine name(s)Topiramate
Primary outcome measureInvestigator-rated dyskinesia severity. To be scored by a blinded assessor from video recordings of participants, every 30 minutes for a total of 150 minutes. Dyskinesia to be rated at each time-point using a 5-point objective dyskinesia intensity rating scale, rating seven body parts (each limb, face, trunk and neck) with a maximum possible score of 28 at each time point. Timepoints of assessment: baseline (week 0), end of Arm 1 (week 6) and end of Arm 2 (week 16)
Secondary outcome measures1. Investigator-rated parkinsonism. Unified Parkinson's Disease Rating Scale (UPDRS) part III to be assessed at 30-minute intervals during clinical assessment. Timepoints of assessment: week 0, 6 and 16.
2. Subject-rated dyskinesia severity:
2.1. Lang-Fahn Activities of Daily Living Dyskinesia Scale. Timepoints of assessment: week 0, 6, and 16.
2.2. Clinical Global Impression of change, assessed weekly during dose titration and at weeks 6 and 16
2.3. UPDRS Part IV. Timepoints of assessment: week 0, 6 and 16.
3. Effects on mood and activities of daily living:
3.1. UPDRS Part I, II. Timepoints of assessment: week 0, 6 and 16.
3.2. Geriatric Depression Scale-15. Timepoints of assessment: week 0, 2, 4, 6, 10, 12, 14 and 16.
4. Excessive daytime sleepiness: Epworth Sleepiness Scale. Timepoints of assessment: week 0, 2, 4, 6, 10, 12, 14 and 16.
Overall study start date01/07/2008
Completion date01/01/2010

Eligibility

Participant type(s)Patient
Age groupOther
SexBoth
Target number of participants30
Key inclusion criteria1. Both males and females, no age limits
2. Patients with Parkinson's disease as defined by UK Parkinson's Disease Society Brain Bank criteria
3. Current use of levodopa, dose to be stable for one month prior to enrolment
4. Stable levodopa-induced dyskinesias
Key exclusion criteria1. Hypersensitivity to topiramate or its excipients
2. Prior surgery for PD
3. Hoehn and Yahr score of 5 when "off"
4. Dementia
5. History of nephrolithiasis, renal impairment, liver disease, glaucoma
6. Pregnancy and breastfeeding
7. Premenopausal females and males not using adequate contraception
8. Use of other antiepileptic drugs, carbonic anhydrase inhibitors, metformin, digoxin or illicit drugs
Date of first enrolment01/07/2008
Date of final enrolment01/01/2010

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Salford Royal NHS Foundation Trust
Salford
M6 8HD
United Kingdom

Sponsor information

Salford Royal NHS Foundation Trust (UK)
Hospital/treatment centre

Clinical Sciences Building
Stott Lane
Salford
M6 8HD
England
United Kingdom

Phone +44 161 206 5137
Email rachel.georgiu@manchester.ac.uk
Website http://www.srht.nhs.uk
ROR logo "ROR" https://ror.org/019j78370

Funders

Funder type

University/education

University of Manchester (UK)
Government organisation / Universities (academic only)
Alternative name(s)
The University of Manchester, University of Manchester UK, University of Manchester in United Kingdom, UoM
Location
United Kingdom

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Editorial Notes

09/05/2016: No publications found, verifying study status with principal investigator.